Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study.
Asthma control
Dupilumab
Lung function
Pediatric asthma
Type 2 Inflammation
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
11 Dec 2023
11 Dec 2023
Historique:
received:
21
07
2023
revised:
22
11
2023
accepted:
03
12
2023
medline:
14
12
2023
pubmed:
14
12
2023
entrez:
13
12
2023
Statut:
aheadofprint
Résumé
Uncontrolled asthma in growing children can impair lung growth that may lead to adverse complications in later life. Dupilumab, a human monoclonal antibody, blocks the shared receptor for interleukins 4 and 13, key drivers of type 2 inflammation. To extensively evaluate the effect of dupilumab on lung function in children (6-11 years) with moderate-to-severe asthma enrolled in phase 3 LIBERTY ASTHMA VOYAGE (NCT02948959). Children with asthma were randomized 2:1 to add-on dupilumab 200/100 mg by bodyweight or placebo every 2 weeks, for 52 weeks. We analyzed spirometry parameters in children with type 2 asthma (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥20 parts per billion [ppb] at baseline), and within subgroups defined by baseline blood eosinophils or FeNO values. 116 (49%) of dupilumab-treated children and 59 (52%) on placebo had impaired lung function (pre-bronchodilator percent-predicted FEV Dupilumab led to significant, sustained lung function improvements across a range of lung function measures in children (6-11 years) with uncontrolled, moderate-to-severe type 2 asthma.
Sections du résumé
BACKGROUND
BACKGROUND
Uncontrolled asthma in growing children can impair lung growth that may lead to adverse complications in later life. Dupilumab, a human monoclonal antibody, blocks the shared receptor for interleukins 4 and 13, key drivers of type 2 inflammation.
OBJECTIVES
OBJECTIVE
To extensively evaluate the effect of dupilumab on lung function in children (6-11 years) with moderate-to-severe asthma enrolled in phase 3 LIBERTY ASTHMA VOYAGE (NCT02948959).
METHODS
METHODS
Children with asthma were randomized 2:1 to add-on dupilumab 200/100 mg by bodyweight or placebo every 2 weeks, for 52 weeks. We analyzed spirometry parameters in children with type 2 asthma (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥20 parts per billion [ppb] at baseline), and within subgroups defined by baseline blood eosinophils or FeNO values.
RESULTS
RESULTS
116 (49%) of dupilumab-treated children and 59 (52%) on placebo had impaired lung function (pre-bronchodilator percent-predicted FEV
CONCLUSIONS
CONCLUSIONS
Dupilumab led to significant, sustained lung function improvements across a range of lung function measures in children (6-11 years) with uncontrolled, moderate-to-severe type 2 asthma.
Identifiants
pubmed: 38092225
pii: S2213-2198(23)01352-1
doi: 10.1016/j.jaip.2023.12.006
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02948959']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.